Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132904 | 0.75 | DYRK1A (0.52) | GRM4DYRK1A | |
| SCHEMBL473390 | 0.75 | GRM4 (0.46) | GRM4MAPK14 | |
| SCHEMBL29414359 | 0.75 | GRM4 (0.39) | GRM4MAPK14 | |
| SCHEMBL421235 | 0.75 | DYRK1A (0.52) | GRM4DYRK1A | |
| SCHEMBL11874314 | 0.75 | GRM4 (0.39) | GRM4MAPK14 | |
| SCHEMBL545813 | 0.75 | GRM4 (0.39) | GRM4MAPK14 | |
| SCHEMBL352379 | 0.75 | GRM4 (0.39) | GRM4MAPK14 | |
| SCHEMBL2619233 | 0.75 | GRM4 (0.39) | GRM4DYRK1AMAPK14 | |
| SCHEMBL3643839 | 0.71 | DYRK1A (0.35) | DYRK1A | |
| SCHEMBL10223032 | 0.71 | GRM4 (0.37) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115279765-B | 1H-pyrazolo [4,3-d ] pyrimidine compounds as Toll-like receptor 7 (TLR 7) agonists | 百时美施贵宝公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-115643805-B | 1H-pyrazolo [4,3-d ] pyrimidine compounds as Toll-like receptor 7 (TLR 7) agonists | 百时美施贵宝公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20230348468-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-11-02 | — | — | US | disclosed |
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-05-11 | — | — | US | disclosed |
| US-20230140430-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-05-04 | — | — | US | disclosed |
| CN-115643805-A | 1H-pyrazolo [4,3-d ] pyrimidine compounds as Toll-like receptor 7 (TLR 7) agonists | 百时美施贵宝公司 | 2023-01-24 | — | — | CN | disclosed |
| EP-4097100-A1 | 1H-PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | Bristol-Myers Squibb Company (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4097108-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | Bristol-Myers Squibb Company (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4097103-A1 | 1H-PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | Bristol-Myers Squibb Company (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115279765-A | 1H-pyrazolo [4,3-d ] pyrimidine compounds as Toll-like receptor 7 (TLR 7) agonists | 百时美施贵宝公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2006071819-A1 | [1H-PYRAZOLO[3, 4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THEORONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| US-7034154-B2 | Synthesis of substituted pyrazolopyrimidines | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-04-25 | — | — | US | disclosed |
| CN-1152033-C | Synthese of substitutd pyrazolopyrimidines | Ŧ����������ѧ��˾ | 2004-06-02 | — | — | CN | disclosed |
| EP-1344768-A2 | Synthesis of substituted pyrazolopyrimidines | Neurocrine Biosciences, Inc. (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1208102-B1 | SYNTHESIS OF A SUBSTITUTED PYRAZOLOPYRIMIDINE | NEUROCRINE BIOSCIENCES INC (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20030004346-A1 | Synthesis of substituted pyrazolopyrimidines | NEUROCRINE BIOSCIENCES, INC. (US) | 2003-01-02 | — | — | US | disclosed |
| US-6472528-B1 | TREATING CONDITIONS WHICH BENEFIT FROM ADMINISTRATION OF AGENTS WHICH POSSESS ANXIOLYTIC, ANTI-ANOXIC, SLEEP-INDUCING, HYPNOTIC, ANTICONVULSANT, AND/OR SKELETAL MUSCLE RELAXANT PROPERTIES. SUCH CONDITIONS INCLUDE INSOMNIA | NEUROCRINE BIOSCIENCES, INC. | 2002-10-29 | — | — | US | disclosed |
| CN-1372561-A | Synthesis of Substituted Pyrazolopyrimidines | NEUROCRINE BIOSCIENCES INC (US) | 2002-10-02 | — | — | CN | disclosed |
| EP-1208102-A1 | SYNTHESIS OF SUBSTITUTED PYRAZOLOPYRIMIDINES | Neurocrine Biosciences, Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001010868-A1 | SYNTHESIS OF SUBSTITUTED PYRAZOLOPYRIMIDINES | NEUROCRINE BIOSCIENCES, INC. (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004346-A1 | Synthesis of substituted pyrazolopyrimidines | INMT, TPMT, HNMT | GRM4 406/4885DYRK1A 2881/4885DYRK1B 3087/4885 |
| US-20230348468-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR9, TLR1 | GRM4 287/4885DYRK1A 3270/4885DYRK1B 3124/4885 |
| US-20230140430-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR1, TLR9 | GRM4 290/4885DYRK1A 3513/4885DYRK1B 3383/4885 |
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR9, TLR1 | GRM4 293/4885DYRK1A 3235/4885DYRK1B 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.